
Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed
Miami, FL
Joined June 2012
- Tweets14.9K
- Following3K
- Followers8.5K
- Likes19.3K
Dr. Estela Rodriguez retweeted
A trial built to pre-empt small cell transformation in TP53/RB1-deficient, EGFR-mutant NSCLC still saw it in nearly half of its patients. The paper, led by Lena Morrill Gavarró and Helena Alexandra Yu, includes our faculty member Charles Rudin (@charlesrudin) among its authors.
🔬 Prospective trial: 1L osimertinib plus platinum and etoposide in EGFR-mutant, TP53/RB1-deficient NSCLC
📊 SCLC transformation in 5 of 11 patients despite SCLC-directed chemotherapy
📊 mPFS 11 mo; mOS 33 mo
📌 Profiling also found mesenchymal and squamous histologies, tied to progressive RB pathway disruption
⚠️ 11 patients and 1 arm, so no comparison with osimertinib alone
Find the single-cell findings on mesenchymal and squamous change in our article.
lungsummit.org/articles/sclc…
A great way to celebrate #LCAM26! 🎉 @FDA accelerated approval of #Neladalkib (Nelkarmi) for previously treated ALK+ advanced NSCLC marks another milestone in two decades of progress—and more hope for our patients. 🫁
▶️ ALKOVE-1: ORR 49% post-alectinib; 32% after ≥2 ALK TKIs + platinum.
🎯 Durable responses: ≥12-month DOR in ~half of responders.
🧠 Promising CNS activity.
⚠️ Key AEs: transaminase elevations, GI effects, myalgias and edema.
An important new salvage option for ALK+ lung cancer, including patients with CNS disease.
#LCSM #ALK @ALKPositiveinc @ALKpositiveINT
🤖 Made with AI
😱 Fascinated and disturbed by this @NEJM_AI analysis where the authors estimate that Heme-Onc speciality work is only 15% Physical and not substitutable by software/AI.
- Can I treat patients w cancer remotely with AI- assisted software? Yes - but is it right?
- Are we moving to a future where patients will be discussing hospice and goals of care, side effects management w machines and not actual doctors? #MedTwitter #AI
The authors analyze the degree to which clinical specialties are shielded from, or threatened by, AI depending on how much of their work requires in-person physical interaction. Learn more: nejm.ai/3UDkrIv

ALT Bar chart titled "Limits to AI Substitution across Specialties: Composition of Medicare Part B Payments Including E&M Services." The chart shows percentages of "Physical," "E&M," and "Nonphysical" services across 15 medical specialties and all overall (US$44.9bn). Total 2023 Medicare Part B payments are shown in parentheses (US$ bn); amounts are in billions of U.S. dollars.
#LCAM26 Every one of these patients has felt the stigma of lung cancer. Every one was told they had incurable cancer at diagnosis. They carry the weight of those words, and so do their families.
This month, I remember their pain, their courage, and the importance of replacing stigma with compassion.
No one deserves lung cancer. Every patient with #lungcancer deserves dignity, support and access to treatment
#LCAM26 #LungCancerAwareness #LCSM
It’s been a weird week. Planes grounded, Outlook down, and now @FDA declines to approve @SMMT_TX ivonescimab for EGFR-mutant lung cancer after osimertinib resistance (HARMONi trial).
Despite a meaningful PFS benefit, lack of demonstrated OS benefit was the deciding factor — a challenging standard, particularly when other cancer drugs have been approved with similar PFS/OS discrepancies in this space 🤷🏽♀️
reuters.com/legal/litigation…
Dr. Estela Rodriguez retweeted
CA Lung Cancer Roundtable in Los Angeles, tomorrow 11/16, hybrid @AmericanCancer @NLCRTnews @ACSCAN @ACSCANCA @nccacs
Dr. Estela Rodriguez retweeted
FDA declines approval of Ivonescimab for 2L
#EGFRmut #NSCLC with chemo due to lack of OS benefit despite the PFS benefit.
Important decision marking a shift in strategy? Chemo+ ami and Dato-DXd got approval in the same setting based on PFS, Should OS be the golden endpoint for 2L approvals ?
reuters.com/legal/litigation…
Here we go again… putting up the Christmas tree 🌲 and trying to keep the cats from climbing it.
Or maybe my cat is just looking for shelter before the next global communications shutdown. 😂
#CatsOfX
Dr. Estela Rodriguez retweeted
🫁 Today is Lung Cancer Screening Day, and we’re OPEN @SylvesterCancer @UMiamiHealth!
🩻 Just like every Saturday, we’re making it easier for you, your patients, & loved ones to get screened!
📞 305-689-LUNG
🔗 sylvesterlungscreening.com
#LCSM #EarlyDetectionSavesLives #LCAM
Dr. Estela Rodriguez retweeted
November is Lung Cancer Awareness Month!
Lung cancer is one of the fields in oncology where research and clinical trials are moving at an extraordinary pace. Yet, the gap between scientific innovation and its implementation in everyday clinical practice is growing.
For me, lung cancer awareness also means recognising this gap, because progress only matters if it reaches patients, globally.
Glad to contribute to #LCAM2026 as a member of the @IASLC Communications Committee.
@Latinamd @MattSmeltzer @CharuAggarwalMD @herbloong @ADesaiMD @lungoncdoc @StephenVLiu @NarjustFlorezMD @DrJNaidoo @ReckampK
#LungCancerAwarenessMonth #IASLC
Dr. Estela Rodriguez retweeted
🏳️🫁 Every Breath Forward Flag Planting Event: University of Illinois-Chicago
The University of Illinois-Chicago ALCSI chapter joined @LUNGevity's Every Breath Forward campaign with an incredible white flag planting event in Chicago, IL!
The team partnered with the nurses and the UI screening center to plant 5,000 white flags honoring lives lost to lung cancer, raising awareness about screening eligibility and the importance of early detection!
This is a powerful display of community, collaboration, and commitment to expanding access to lifesaving lung cancer screening!!! 🙌💙
#LungCancerAwareness #ScreeningSavesLives #ALCSI #UICALCSI #EveryBreathForward #LCAM @thisisUIC
Glad that @ABIMcert continues to report the diversity of newly certified Medical Oncology diplomates in its 2026 Annual Report. But it’s disappointing to see how little progress we’ve made over time.
Still, only 6% of Med Onc diplomates identify as Latino and 4% as Black.
#Diversitymatters. #Representationmatters. We need sustained investment in early STEM education, mentorship, and pathways into medicine and oncology to build a more diverse future workforce.
Source: ABIM 2026 Annual Report.
@LatinxOncology
Dr. Estela Rodriguez retweeted
One of the best parts of any meeting is reconnecting with old friends and making new ones!
#ITMIG_LALCA2026
@Itmig_society @IASLC
Dr. Estela Rodriguez retweeted
Great panel discussion during the systemic therapy session, chaired by Dr. @eripietroluongo @ClaudioVladmir!
#ITMIG2026
#LALCA26 @IASLC 🇧🇷
Simon Bolivar said it best: “In the unity of our nations rests the glorious future of our peoples.”
Obrigada to the #LATAM26 CoChairs @clarissamathias and Dr William William🇧🇷 , for the opportunity to spend time with so many amazing thoracic oncologists, researchers, and patient advocates. Grateful for the knowledge shared, the meaningful conversations, and our collective commitment to advancing research and improving patient care across Latin America. 🫁❤️
#LATAM #GlobalOnc #LungCancer
🤖 Made with AI
#LATAM26 @IASLC 🇧🇷 Excited to be part of this panel discussing the new frontiers of bispecific antibodies and antibody-drug conjugates (ADCs) in lung cancer—with and without actionable mutations.
Beyond efficacy, we need to tackle toxicity management, optimal sequencing, and, most importantly, a critical question:
What is the added value 💲 of these innovative therapies in resource-constrained settings❓
Innovation must translate into meaningful, accessible patient benefit across Latin America and beyond. 🌎🫁 #LCSM #GlobalOnc @SylvesterCancer
#LATAM26 @IASLC 🇧🇷 Valuable take-home messages from the amazing Dr. Paula Ugalde @paugalde20 @MassGenBrigham on approaching borderline-resectable Stage III NSCLC.
Key principles:
1️⃣multidisciplinary assessment, 2️⃣reassessing resectability after induction therapy, and
3️⃣offering surgery only when an R0 resection is achievable.
Because every step matters! 🫁 #LCSM
🤖 Made with AI
#LATAM26 @IASLC 🇧🇷 Day 3 opens with an excellent discussion on Stage III NSCLC management, highlighting surgical, radiation, and medical oncology perspectives and the importance of multidisciplinary teams in #LATAM
With Drs. Paula Ugalde, Fabio Moraes, and Tatiana Montella.
🌎Different continent, same challenge : how to approach borderline-resectable disease! #lcsm

































